Drugs / nL-SCN2A-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06314490 | Feb 2024 → Feb 2026 overdue | disease of genetic or genomic mechanism | University of California, San Diego | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-SCN2A-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06314490 ↗ |
| Modality | Antisense oligonucleotide | “personalized antisense oligonucleotide (ASO) drug” NCT06314490 ↗ |